A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall ...

Let’s cover six scientifically backed methods to address the post-stem cell transplant procedure side effects you may be experiencing.

Mesoblast’s achievement in winning approval for its Ryoncil drug in the US in December heralds the arrival of a new class of ...

Pegtarazimod is under clinical development by ReAlta Life Sciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury.

Dorocubicel is under clinical development by ExCellThera and currently in Phase II for Blood Cancer. According to GlobalData, Phase II drugs for Blood Cancer have a 34% phase transition success rate ...

Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.

The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...